BioTime (BTX) Affirms Announcement of Positive AST-OPC1 SCiSTAR Phase 1/2a Data (AST)

September 15, 2016 4:08 PM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

BioTime, Inc. (NYSE: BTX) announced that its affiliate, Asterias Biotherapeutics, announced positive interim efficacy data from the AST-OPC1 SCiSTAR Phase 1/2a clinical study in patients with complete cervical spinal cord injuries at the 55th Annual Scientific Meeting of the International Spinal Cord Society (ISCoS) on September 14, 2016.

For additional information on the data, please see the ISCoS conference presentation on Asterias’ website at: as well as:

“The positive efficacy data from the AST-OPC1 SCiSTAR study reinforces our belief in the unique regenerative potential of pluripotent stem cell-derived therapeutics. An additional example is OpRegen®, which is in a Phase 1/2a study for treating dry-AMD. These and other products in our pipeline have the potential to be first-in-class products addressing the large unmet needs associated with degenerative disease,” said Michael D. West, Ph.D., BioTime’s Co-Chief Executive Officer.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Related Entities


Add Your Comment